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Background: Dabigatran is one of the three newer oral anticoagulants (OACs) recently approved in the United States
for stroke prevention in non-valvular atrial fibrillation (NVAF) patients. The objective of this study was to identify patient,
healthcare provider, and health plan factors associated with dabigatran versus warfarin use among NVAF patients.
Methods: Administrative claims data from patients with ≥2 NVAF medical claims in the HealthCore Integrated
Research Database between 10/1/2009 and 10/31/2011 were analyzed. During the study intake period (10/1/2010 - 10/
31/2011), dabigatran patients had ≥2 dabigatran prescriptions, warfarin patients had ≥2 warfarin and no dabigatran
prescriptions, and the first oral anticoagulant (OAC) prescription date was the index date. Continuous enrollment
for 12 months preceding (“pre-index”) and ≥ 6 months following the index date was required. Patients without
pre-index warfarin use were assigned to the ‘OAC-naïve’ subgroup. Separate analyses were performed for ‘all-patient’
and ‘OAC-naïve’ cohorts. Multivariable logistic regression (LR) identified factors associated with dabigatran versus
warfarin use.
Results: Of 20,320 patients (3,019 dabigatran and 17,301 warfarin) who met study criteria, 27% of dabigatran and
13% of warfarin patients were OAC-naïve. Among all-patients, dabigatran patients were younger (mean 67 versus
73 years, p < 0.001), predominantly male (71% versus 61%, p < 0.001), and more frequently had a cardiologist
prescriber (51% versus 30%, p < 0.001) than warfarin patients. Warfarin patients had higher pre-index Elixhauser
Comorbidity Index (mean: 4.3 versus 4.0, p < 0.001) and higher ATRIA bleeding risk score (mean: 3.0 versus 2.3,
p < 0.001). LR results were generally consistent between all- and OAC-naïve patients. Among OAC-naïve patients,
strongest factors associated with dabigatran use were prescriber specialty (OR = 3.59, 95% CI 2.68-4.81 for
cardiologist; OR = 2.22, 95% CI 1.65-2.97 for other specialist), health plan type (OR = 1.47 95% CI 1.10-1.96 for
preferred provider organization), and prior ischemic stroke (OR = 1.42, 95% CI 1.06-1.90). Older age decreased
the probability of dabigatran use.
Conclusions: Beside patient characteristics, cardiology specialty of the prescribing physician and health plan type
were the strongest factors associated with dabigatran use.
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Three new oral anticoagulants (OACs) [dabigatran, riv-
aroxaban, and apixaban] have recently been approved
for stroke prevention in atrial fibrillation (AF) patients
in the United States (US). These new agents have fixed
dosing regimens, do not require routine monitoring of
the patient’s coagulation status, and have less food-drug
interaction potential than warfarin [1-3]. In a randomized
clinical trial, dabigatran 150 mg was superior in stroke
reduction and similar in the risk of major bleeding
compared to warfarin [4]. In a double-blind randomized
clinical trial, rivaroxaban was shown to have similar efficacy
in stroke prevention as warfarin based on an intent-to-treat
analysis, but superior efficacy and similar risk of major
bleeding compared to warfarin based on a per protocol
analysis [5]. Clinical trial results also indicated a significant
reduction in the risk of stroke and risk of major bleeding
was associated with apixaban compared to warfarin [6].
Overall, these OACs have been found to have either similar
or better efficacy or safety profiles, offer more therapeutic
options and may provide better outcomes for stroke pre-
vention among AF patients compared to warfarin [4-6].
The American College of Chest Physicians (ACCP) 2012
guidelines recommend that in the absence of elevated
bleeding risk or contraindications, patients at increased
risk of stroke should be treated with an OAC [7]. Despite
the availability and the established safety of OACs, they
are underutilized among patients with non-valvular atrial
fibrillation (NVAF) for whom OAC use is indicated [8].
High bleeding risk, perceived low stroke risk, brief dur-
ation of AF, and personal preference have been cited by
physicians as reasons for not prescribing warfarin to
patients with AF [9].
Due to the recent availability of the newer OACs, little
research exists about patient, healthcare provider, and
health plan factors related to their use compared to
warfarin among NVAF patients in the real-world. This
research is needed because patient and health plan charac-
teristics, [10-12], along with specialty characteristic of
the healthcare provider [13-15] have been shown to
affect patient use of treatment and/or patient outcomes
in cardiovascular and other diseases. Cost, safety and
efficacy, patient preference, and cardiology specialty
may be important factors affecting the choice of OAC
among likely dabigatran users [16]. This study sought
to identify patient, provider, and health plan character-
istics associated with the use of dabigatran versus
warfarin among a large cohort of NVAF patients using
real-world data.
Methods
Study population and inclusion criteria
The study was a retrospective analysis of medical and
pharmacy claims utilizing administrative claims data fromthe HealthCore Integrated Research Database (HIRDSM),
a large database of administrative claims for from a
large health benefits organization. The HIRDSM contains
longitudinal claims data for approximately 45 million
patients belonging to 14 health plans in the Northeastern,
Southern, Midwestern, and Western regions of the US; it
includes patients covered by health maintenance organiza-
tions (HMOs), preferred provider organizations (PPOs),
and other health plans (including point of service (POS),
consumer-directed health, and indemnity health plans).
All study materials were handled in compliance with
the Health Insurance Portability and Accountability Act
(HIPAA), and a limited dataset (as defined in the Privacy
Regulations issued under HIPAA) was used for this
analysis. Patient confidentiality was preserved and the
anonymity of all patient data was safeguarded through-
out the study. Institutional Review Board approval was
not required for this retrospective observational study
in which researchers only had access to a limited data set
that excluded specified patient identifiers and consisted of
anonymized patient information.
Patient identification
Eligible patients were identified from the HIRDSM during
the study period from October 1, 2009 to April 30, 2012.
Patient aged 18 years or older were required to have at
least two medical claims for AF as primary or secondary
diagnosis (ICD-9-CM code 427.31) separated by at least
30 days between October 1, 2009 and October 31, 2011.
At least one of these AF medical claims had to be an
outpatient claim and both were required to occur prior
to or coincide with the study index date (see below for
definition). Patients were classified into dabigatran and
warfarin cohorts based on their OAC prescription claims
filled during the study intake period (from October 1,
2010 to October 31, 2011). During the intake period,
dabigatran patients had ≥2 dabigatran prescriptions,
warfarin patients had ≥2 warfarin and no dabigatran
prescriptions, and the first OAC prescription fill date
served as the index date. Continuous health plan en-
rollment for 12 months preceding (“pre-index period”)
and ≥ 6 months following the index date was required.
Patients with valvular heart disease/valve replacement
or hyperthyroidism (determined via ICD-9-CM codes
(Table 1) in the 12-month pre-index period were excluded.
Patients without any prescription claims for an oral anti-
coagulant during the pre-index period were classified as
oral anticoagulant naïve (OAC-naïve) patients. Separate
analyses were performed for the ‘all-patient’ and ‘OAC-
naïve’ cohorts.
Study measures of interest
The primary outcome variable was use of dabigatran or
warfarin on the study index date. Independent variables
Table 1 Patient exclusion criteria
Condition ICD-9 diagnosis codes ICD-9 procedure codes HCPCS codes CPT codes




- 33400-33496, 33600, 33602, 33660,
33665, 33670, 33684, 92986-92990
Hyperthyroidism 242 - - -
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clinical characteristics, healthcare provider specialty, and
health plan factors. Demographic characteristics included
patient age (at the index date) and gender. Healthcare
variables included health plan geographic location
(Northeast, Midwest, South, West), and type of health
plan [HMO, PPO, other]. A healthcare provider factor
(the index OAC prescriber specialty (cardiology, primary
care/family/internal medicine,other specialty) was exam-
ined. Total patient pre-index out-of-pocket prescription
drug costs were calculated.
Comorbid conditions were identified by ICD-9-CM codes
associated with medical claims at any position during the
pre-index period and included the following: coronary
artery disease, myocardial infarction, cardiomyopathy,
prior ischemic stroke, prior transient ischemic attack
(TIA), prior bleed, heart failure, hypertension, peripheral
artery disease, diabetes, and stages II-V chronic kidney
disease. In addition, the Elixhauser comorbidity index
(ECI) [17,18] was used to assess patient overall pre-index
comorbidity burden, using ICD-9-CM codes for 30 condi-
tions associated with medical claims during the pre-index
period. CHADS2 [19] stroke risk factors and total score
(calculated based on presence of heart failure (HF),
hypertension, diabetes, prior stroke/TIA, and age >75 years)
and ATRIA [20] bleeding risk scores (calculated based
on presence of anemia, severe renal disease, any prior
hemorrhage diagnosis, hypertension, and age ≥75 years)
were calculated for study cohorts. AF-related procedures
(heart rate and heart rhythm procedures, including inser-
tion of pacemaker or defibrillator, cardioversion, surgical
ablation, and left atrial catheter ablation) during the pre-
index were assessed.
Additionally, pharmacy prescriptions dispensed during
the pre-index period were described for the following
medications: warfarin (all-patients cohort only), parenteral
anticoagulants (enoxaparin, tinzaparin, dalteparin, fonda-
parinux), anti-platelet therapy/NSAIDS (clopidogrel, tica-
grelor, prasugrel, ticlopidine, cilostazol, dipyridamole, and
non-steroidal anti-inflammatory agents [NSAIDS]), heart
rate control medications (beta-blockers, calcium channel
blockers, digoxin/digitoxin), antiarrhythmic medications
(dronedarone, amiodarone, disopyramide, procainamide,
flecainide, propafenone, sotalol, deofetilide, quinidine,
mexiletine, moricizine), and dyspepsia medications (pro-
ton pump inhibitors and histamine receptor antagonists).
Finally, the presence of ≥1 prothrombin time (PT) testduring the pre-index period was assessed (all-patients
cohort only) as a proxy for presence of ≥1 INR tests.Statistical analysis
Patient demographic and clinical characteristics, health-
care provider specialty, and health plan factors associated
with dabigatran or warfarin use on the index date were
analyzed separately for all-patient and OAC-naïve patient
cohorts. Two-sample t-tests were used to test differences
between continuous variables, chi-square tests were used
to test differences between categorical variables, and
Wilcoxon rank-sum tests were used to test differences
in the cost variables between the dabigatran and war-
farin cohorts.
Multivariable logistic regression (LR) with backward
elimination was used to identify significant factors asso-
ciated with dabigatran (reference group = warfarin) use.
Separate LR models were conducted for all-patient and for
OAC-naïve patient cohorts. The following independent
variables were used in the LR models: patient age in years
(defined as 18–54, 55–64, 65–74, 75–84, and ≥85), patient
gender, ECI score, ATRIA bleeding risk score, separate
indicator variables for the presence of relevant pre-index
comorbidities (HF, hypertension, diabetes, ischemic stroke,
transient ischemic attack, stages II-V chronic kidney dis-
ease); indicator variable for pre-index AF-related proce-
dures; pre-index use of warfarin, pre-index PT test (only
among all-patient cohort); separate indicator variables for
pre-index use of parenteral anticoagulants, anti-platelet/
NSAIDS therapy, heart rate control medications or antiar-
rhythmic medications, and dyspepsia medications; and
health plan variables (health plan type and geographic
region), the specialty of index OAC prescriber, and total
patient pre-index out-of-pocket prescription drug costs.
Female and age group variables were forced into the
LR models.Results
Descriptive analysis results
Overall, 20,320 patients who received either dabigatran
or warfarin therapy on the index date met the study criteria
(“all-patient cohort”): 14.9% (3,019) received dabigatran,
while 85.1% (17,301) received warfarin. Among patients
who received dabigatran, 464 (15.4%) also received warfarin
prescriptions during the study follow-up. Among OAC-
naïve patients (n = 2,405): 815 (33.9%) patients received
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dabigatran prescriptions during the pre-index period.
Patient demographic and clinical characteristics, health-
care provider specialty, and health plan factors between
dabigatran and warfarin cohorts were comparable
among the all-patient and OAC-naïve cohorts (Table 2).
Dabigatran patients were significantly younger than
warfarin patients [all-patient cohort: mean (SD) age 67
(11.4) versus 73 (11.4) years, p < 0.0001; OAC-naïve
cohort: mean (SD) age 65 (11.9) versus 71 (12.1) years,
p < 0.0001] and less frequently females (all-patient: 29.1%
versus 39.2%, p < 0.001; OAC-naïve: 27.5% versus 35.4%,
p < 0.0001). Among all- and OAC-naïve patients, dabiga-
tran users were more frequently covered by a preferred
provider organization (PPO) benefit design than a HMO
benefit design (all-patient: 67.8% versus 49.3%, p < 0.0001;
OAC- naïve: 68.2% versus 52.9%, p < 0.0001). Compared
to warfarin, dabigatran use was less frequent in theTable 2 Pre-index patient demographic, healthcare provider,





N/mean %/SD N/mean %
Patient demographic variables
Age (years), n,%
18-44 57 1.9 147 0
45-54 297 9.8 897 5
55-64 1,040 34.4 3,299 1
65-74 777 25.7 4,213 2
75-84 619 20.5 5,969 3
85+ 229 7.6 2,776 1
Age, mean, SD 67 ±11.4 73 ±1
Female 878 29.1 6,775 3
Health plan and healthcare provider variables
Insurance plan, n,%
Preferred provider organization 2,047 67.8 8,522 4
Health maintenance organization 396 13.1 4,136 2
Other 576 19.1 4,643 2
Health plan region, n,%
Midwest 648 21.5 6,333 3
Northeast 720 23.8 4,257 2
West 966 32.0 3,962 2
South 685 22.7 2,749 1
Physician specialty, n,%
Cardiology 1,541 51.0 5,234 3
Primary care/internal medicine 424 14.1 6,132 3
Other 1,054 34.9 5,935 3
Patient out of pocket pharmacy
costs during the pre-index period
$1,012 $1,585 $952 $1Midwest (all-patient: 21.5% versus 36.6%, p < 0.001;
OAC-naïve: 22.7% versus 44.9%, p < 0.0001) and more
frequent in the West health plans (all-patient: 32.0%
versus 22.9%, p < 0.001; OAC-naïve: 32.1% versus 22.4%,
p < 0.0001). Patients were more likely to be prescribed
dabigatran as their index OAC by a cardiologist (rather
than a primary care, or other provider) than warfarin
patients (all-patient: 51.0% versus 30.3%, p < 0.001; OAC-
naïve: 51.3% versus 32.7%, p < 0.001). Mean patient out-
of-pocket pharmacy costs during the pre-index period
was higher for dabigatran than warfarin patients [all-
patient: mean (SD) $1,012 ($1,585) versus $952 ($1,050),
p < 0.0001; OAC-naïve: mean (SD) $870 ($2,135) versus
$655 ($735), p < 0.0001].
Compared to warfarin patients, dabigatran patients had
lower CHADS2 risk scores (all patients: mean (SD) 1.9
(1.3) versus 2.2 (1.3), p < 0.0001; OAC- naïve: mean (SD)








/SD N/mean %/SD N/mean %/SD
.8 <.0001 30 3.7 22 1.4 <.0001
.2 108 13.3 132 8.3
9.1 313 38.4 363 22.8
4.4 191 23.4 375 23.6
4.5 124 15.2 486 30.6
6.0 49 6.0 212 13.3
1.4 <.0001 65 ±11.9 71 ±12.1 <.0001
9.2 <.0001 224 27.5 563 35.4 <.0001
9.3 <.0001 556 68.2 841 52.9 <.0001
3.9 108 13.3 308 19.4
6.8 151 18.5 441 27.7
6.6 <.0001 185 22.7 714 44.9 <.0001
4.6 175 21.5 300 18.9
2.9 262 32.1 356 22.4
5.9 193 23.7 220 13.8
0.3 <.0001 418 51.3 520 32.7 <.0001
5.5 75 9.2 418 26.3
4.2 322 39.5 652 41.0
,050 0.0080 $870 ±$2,135 $655 ±$735 0.0003
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OAC- naïve: mean (SD) 2.0 (2.0) versus 3.1 (2.6), p <
0.0001)) (Table 3). Dabigatran patients also had fewer
pre-index comorbidities than warfarin patients (all patient:
mean (SD) ECI 4.0 (2.2) versus 4.3 (2.3), p < 0.0001; OAC-
naïve: mean (SD) ECI 3.7 (2.1) versus 4.5 (2.6), p < 0.0001).
Dabigatran patients more frequently had a history of
ischemic stroke or TIA, but less frequently had hyperten-
sion, diabetes, and HF than warfarin users. Dabigatran
patients more frequently had pre-index AF-related pro-
cedures than warfarin patients among the all-patient
cohort (5.1% versus 2.5%, p < 0.0001), but there was no
significant difference in the proportion of patients with
pre-index stroke/TIA or AF-related procedures between
OAC-naïve dabigatran and OAC-naïve warfarin patients.
Among the all-patient cohort, more warfarin patients
used warfarin during the pre-index period compared
to dabigatran patients (90.8% versus 73.0%, p < 0.0001)









CHADS2, mean, SD 1.9 ±1.3 2.2
ATRIA, mean, SD 2.3 ±2.1 3.0
Elixhauser (ECI), mean, SD 4.0 ±2.2 4.3
Selected pre-index comorbidities, n,%
Any ischemic stroke 497 16.5 2,56
Any TIAs 169 5.6 789
Heart failure 603 20.0 4,59
Hypertension 2,394 79.3 14,20
Diabetes mellitus 895 29.6 5,68
Chronic kidney disease (stages II-V) 172 5.7 1,26
Heart rate and heart rhythm control procedures* 155 5.1 436
Pre-index use of selected medications
Use of warfarin, n,% 2,204 73.0 15,71
≥1 PT tests, n,% 2,111 69.9 13,57
Parenteral anticoagulants, n,% 231 7.7 974
Any platelet inhibitor 648 21.5 2,76
Prescription NSAIDs 456 15.1 1,79
Any rate control medication 2,475 82.0 13,91
Any rhythm control medication, n,% 948 31.4 3,23
Any rate or rhythm control medications 2,562 84.86 14,22
Any dyspepsia medication, n,% 749 24.8 4,12
Proton-pump inhibitor (PPI) 689 22.8 3,70
Histamine type-2 receptor antagonist (H2RA) 100 3.3 583
*Includes insertion of pacemaker or defibrillator, cardioversion – electrical, left atriaanti-platelet agents/NSAIDS than warfarin patients during
the pre-index period among both the all-patient and
OAC-naïve cohorts (all-patient: 21.5% versus 16.0%,
p < .00001; OAC- naïve: 27.6% versus 21.4%, p < 0.0007).
Use of parenteral anticoagulants was more common
among dabigatran users in the all-patient cohorts, but less
frequent among dabigatran than warfarin patients in
the OAC-naïve patients (all patient: 7.7% versus 5.6%,
p < 0.0001; OAC-naïve: 1.6% versus 3.7%, p < 0.0040). Use
of any heart rate or rhythm control medication was more
common among dabigatran than warfarin patients (all-pa-
tient: 84.9% versus 82.2%, p < 0.0004; OAC-naïve: 80.2%
versus 73.2%, p < 0.0001). Among the all-patient cohort,
warfarin users were more likely to have ≥1 PT tests during
the pre-index period (90.8% versus 73.0%, p < 0.0001).
Multivariable LR results
The factors that were significantly associated with dabi-








an %/SD N/mean %/SD N/mean %/SD
±1.3 <.0001 1.7 ±1.4 2.2 ±1.4 <.0001
±2.3 <.0001 2.0 ±2.0 3.1 ±2.6 <.0001
±2.3 <.0001 3.7 ±2.1 4.5 ±2.6 <.0001
7 14.8 0.0213 127 15.6 259 16.3 0.6550
4.6 0.0131 46 5.6 90 5.7 0.9870
2 26.5 <.0001 136 16.7 445 28.0 <.0001
2 82.1 0.0003 626 76.8 1,288 81.0 0.0157
3 32.8 0.0005 207 25.4 508 31.9 0.0009
5 7.3 0.0014 45 5.5 154 9.7 0.0005
2.5 <.0001 44 5.4 66 4.1 0.1656
1 90.8 <.0001 0 0.0 0 0.0 NA
5 78.5 <.0001 NA NA NA NA NA
5.6 <.0001 13 1.6 59 3.7 0.0040
8 16.0 <.0001 225 27.6 341 21.4 0.0007
1 10.4 <.0001 145 17.8 190 11.9 <.0001
6 80.4 0.0472 614 75.3 1,119 70.04 0.0103
8 18.7 <.0001 286 35.1 353 22.2 <.0001
3 82.21 0.0004 654 80.3 1,164 73.2 0.0001
2 23.8 0.2424 173 21.3 362 22.8 0.3900
1 21.4 0.0781 159 19.5 320 20.1 0.7201
3.4 0.8717 26 3.2 55 3.5 0.7293
l catheter ablation and surgical ablation.
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pothesis for lack of model fit was rejected based on a
Hosmer and Lemeshow test for the all-patients model
(p-value = 0.6416) and for the OAC-naïve patients model
(p-value = 0.0754), indicating that both models fit the
data well. In both analyses, the adjusted odds of dabigatran
use decreased with increasing patient age among patients
65 or older (range of OR = 0.39-0.64; all p ≤ 0.0001
Table 4). Females had slightly lower odds of dabigatran
use compared to males (adjusted OR = 0.87, 95% CI 0.79-
0.96) in the all-patient analysis but female gender was not a
significant predictor in the OAC-naïve analysis. Dabigatran
use was also less likely among patients in Midwestern
health plans than health plans in the West (all-patient:
adjusted OR = 0.55, 95% CI 0.49-0.62; OAC-naïve: adjusted





Female (reference =male) 0.87 0.7
55-64 age group (reference = 18–54) 1.00 0.8
65-74 age group 0.64 0.5
75-84 age group 0.44 0.3
85+ age group 0.39 0.3
Midwest region indicator (reference = west) 0.55 0.4
Northeast region indicator 0.90 0.8
South region indicator 1.05 0.9
PPO insurance indicator (reference = HMO) 1.68 1.4
Other insurance type indicator 1.31 1.1
Total ATRIA score 0.98 0.9
Pre-index heart failure 0.78 0.7
Pre-index hypertension 1.16 1.0
Pre-index warfarin 0.34 0.3
Pre-index any anti-platelet/NSAIDS fill 1.15 1.0
Prior use of any dyspepsia medication 1.13 1.0
Cardiology specialty of index OAC prescriber indicator
(reference = PCP/family/internal medicine)
3.12 2.7
Other specialty of index OAC prescriber 1.94 1.7
Pre-index PT test use 0.70 0.6
Pre-index any heart rate/rhythm control medication fill 1.19 1.0
Pre-index any Afib related procedure 1.53 1.3
Pre-index ischemic stroke 1.34 1.1
Pre-index TIA 1.24 1.0
Total patient out of pocket pharmacy costs (per $1 K)
during the pre-index period
1.04 1.0
†C-statistic = 0.7530; Hosmer and Lemeshow Test (p-value = 0.6416).
#C-statistic = 0.7360; Hosmer and Lemeshow Test (p-value = 0.0754).and OAC-naïve patient cohorts, pre-index hypertension
(all-patient: adjusted OR = 1.16, 95% CI 1.04-1.30; OAC-
naïve: adjusted OR = 1.32, 95% CI 1.04-1.69) and ischemic
stroke (all-patient: adjusted OR = 1.34, 95% CI 1.18-1.53;
OAC-naïve: adjusted OR = 1.42, 95% CI 1.06-1.90) were
associated with greater odds of dabigatran use. For both
the all-patient and OAC-naïve patient cohorts, pre-index
HF and higher risk of bleeding (based on ATRIA score)
were associated with lower adjusted odds of dabigatran
use. Among the all-patient cohort, prior use of warfarin
was strongly associated with lower adjusted odds of
dabigatran use (OR = 0.34, 95% CI 0.31-0.38). For the all-
patient cohort only, pre-index AF-related procedures,
anti-platelet/NSAID medications, dyspepsia medications,
rate/rhythm control medications, and pre-index TIA were
all positively associated with dabigatran use; odds ratios) among all patients (n = 20,320) and OAC-naïve patients
ient cohort† OAC-naïve cohort#
confidence
limits




9 0.96 0.0035 1.02 0.83 1.26 0.8362
6 1.16 0.9517 0.90 0.68 1.21 0.4865
5 0.75 <.0001 0.59 0.43 0.81 0.0010
7 0.53 <.0001 0.40 0.28 0.58 <.0001
1 0.48 <.0001 0.42 0.26 0.66 0.0002
9 0.62 <.0001 0.43 0.34 0.56 <.0001
0 1.01 0.0816 0.93 0.70 1.23 0.6125
3 1.19 0.4389 1.12 0.85 1.49 0.4282
8 1.92 <.0001 1.47 1.10 1.96 0.0089
3 1.52 0.0003 1.20 0.87 1.66 0.2770
5 1.00 0.0477 0.91 0.86 0.96 0.0005
0 0.87 <.0001 0.76 0.59 0.97 0.0253




7 3.51 <.0001 3.59 2.68 4.81 <.0001




8 1.53 <.0001 1.42 1.06 1.90 0.0183
2 1.51 0.0281
1 1.08 0.0251 1.32 1.17 1.48 <.0001
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Table 4.
Health plan characteristics were significantly associated
with the odds of dabigatran use, adjusted for other factors
(Table 4). Specifically, patients covered by PPO benefit
designs were 68% and 47% more likely to be prescribed
dabigatran than patients covered by HMO benefit designs
in the all patient and OAC-naïve cohorts, respectively.
Compared to patients prescribed their index OAC by a
primary care/family/internal medicine physician, patients
whose index OAC was prescribed by a cardiologist (all-pa-
tient: adjusted OR = 3.12, 95% CI 2.77-3.51; OAC-naïve:
adjusted OR = 3.59, 95% CI:2.68-4.81) or other specialist
(all-patient: adjusted OR = 1.94, 95% CI 1.72-2.20; OAC-
naïve: adjusted OR = 2.22, 95% CI:1.65-2.97) were more
likely to receive dabigatran. Finally, for both study cohorts,
higher total pre-index period patient out-of-pocket phar-
macy costs (per $1,000) were associated with greater
odds of dabigatran use (all-patient: adjusted OR = 1.04,
95% CI 1.01-1.08; OAC-naïve: adjusted OR = 1.32, 95%
CI:1.17-1.48).
Discussion
Overall, our study found that dabigatran was the oral
anticoagulant prescribed for 34% of OAC-naïve patients
with NVAF, and that patient demographic and baseline
clinical characteristics were related to the use of dabiga-
tran versus warfarin. Consistent with findings of other
studies that physicians are less likely to use anticoagula-
tion among older patients, even though older patients
have a greater risk of stroke [21-23], this study found
that warfarin (as compared to dabigatran) was more
likely to be prescribed to older patients. This study also
found that patients with a history of HF and those with
prior renal function impairment were less likely to use
dabigatran. Furthermore, we found that patients who
received warfarin therapy previously were less likely to
receive dabigatran, and only about 15% of patients who
received dabigatran on the index date received warfarin
prescriptions after the index date among the all-patient
cohort.
Patients with a higher bleeding risk were less likely to
use dabigatran. This is an interesting finding because
the lack of a monitoring assay and reversal agent for
dabigatran therapy have been important safety concerns
for clinicians; cases of bleeding events associated with
dabigatran, especially in elderly patients with impaired
renal function, have been published in the literature
and have received recent regulatory attention in the US
and elsewhere [24-28]. Compounded with the fact that
dabigatran demonstrated an increased risk of intracra-
nial bleeding among patients aged 75 years and older in
a phase 3 study, it is not surprising that warfarin use
was more frequent among those with a higher risk ofbleeding [29]. While the Food and Drug Administration
(FDA) is continuing to monitor new sources of drug
surveillance data, they have concluded that bleeding
rates associated with new dabigatran use do not appear
to be greater than those associated with new warfarin
use [28].
Cardiologists were significantly more likely to prescribe
dabigatran than other physician types. This finding is
consistent with prior research [30,31] that found that
specialists tend to be early adopters of new drugs. Given
that our study used data corresponding to the first year
subsequent to dabigatran approval in the US, cardiologists
were possibly more familiar with the literature regarding
the use of the newly approved dabigatran than other spe-
cialists. Indeed, among 65 prescribers surveyed in a study
by Huang et al., who were primarily general internists,
63% cited limited experience with dabigatran as a reason
for not prescribing dabigatran; compared to cardiologists,
general internists were less likely to prescribe dabigatran
to OAC-naïve patients due to limited experience with
dabigatran (31% versus 69%, p = 0.02) [16]. In addition,
health plan factors were associated with the choice of
OAC therapy. Particularly, patients covered by PPO bene-
fit designs were more likely to receive dabigatran than pa-
tients covered by HMO benefit designsand patients with
health plans located in the West region were more likely
to receive dabigatran than patients who lived in the
Midwest. According to the Kaiser Family Foundation's
Employer Health Benefits 2010 Annual Survey, HMO
enrollment is significantly higher in the West and
Northeast and significantly lower in the South and
Midwest [32]. Differences in regional practice variations
could be behind the variations in the use of dabigatran.
Previous studies have consistently found that increasing
copayment amounts lead to a reduction in the use of
drugs [33-35]. However, data on how prior out-of-pocket
costs predict future medication costs is limited. In our
study, patients with higher pre-index out-of-pocket pre-
scription drug costs were more likely to receive dabigatran
than warfarin.
Further research is needed to better understand the
role of patient income and sociodemographic variables
and prior prescription drug expenditures as they relate
to patients’ willingness-to-pay for dabigatran. Factors
related to OAC therapy choice may change over time as
prescribers and patients gain more familiarity and ex-
perience with the newer OACs, and additional research
will be needed to identify predictors of treatment and
changes in OAC treatment patterns in the future. Also,
as recommended by the European Society of Cardiology
[36] and the American College of Chest Physicians [37],
future research needs to consider the impact of patient
preferences in OAC therapy decisions. This is important
because prior treatment experience and the value that
AbuDagga et al. BMC Health Services Research 2014, 14:310 Page 8 of 9
http://www.biomedcentral.com/1472-6963/14/310patients place on stroke prevention and bleeding risk
affect patients’ willingness to take warfarin [38,39].Limitations
Several limitations should be noted in the interpretation
of our study’s findings. Although a number of relevant
patient factors were analyzed in this study, other patient
factors such as patient socioeconomic status, race, and
use of over-the-counter medications such as NSAIDs, are
not available in administrative claims and therefore were
not included. We were not able to assess patient aware-
ness of dabigatran therapy through direct-to-consumer
advertising, nor were we able to control for any effect that
treatment outcomes (e.g., bleeding) associated with prior
warfarin therapy may have had on dabigatran use in our
analyses. Nevertheless, the findings of this study were
consistent in the all-patient and OAC-naïve cohorts
and support the robustness of this study.Conclusions
Factors associated with use of newer oral anticoagulant
therapy include patient demographic and clinical charac-
teristics, specialty of the healthcare provider, health plan
type, and prior prescription out-of-pocket costs. Cardi-
ology specialty of prescribing physician and PPO health
plan were the strongest predictors of dabigatran use
among all study patients with NVAF, and likelihood of
dabigatran use decreased with increasing patient age.
Newer studies are warranted to understand prescriber
treatment patterns with available OACs. Additional re-
search is needed as more real-world data becomes available
to further examine the use of the newer OACs versus war-
farin related to the potential impact on the quality of antic-
oagulation care.
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